Optimization of a New Adaptive Intervention to Increase COVID-19 Testing: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Optimization of a New Adaptive Intervention to Increase COVID-19 Testing (NCT04757298), a randomized na study. The primary outcome is Stage 1: Completion of COVID-19 Test After First Randomization.

2. Clinical Question

Statistically, this is an evaluation of a sequential intervention strategy rather than a record of a single, fully reported treatment contrast. Initial assignment determines whether participants enter a navigation or brochure pathway. Some participants are then randomized to an additional behavioral component, while other pathways continue with the initial approach. The registry describes these pathways but does not provide results that would establish how testing completion differed between them.

The study’s stated aim is to optimize an adaptive intervention and to use an integrated research collaborative framework to facilitate dialogue among researchers, community members, and service providers. That context helps explain why the intervention includes several behavioral components and stages. It does not, by itself, establish which component or sequence had a larger effect. The primary question remains specific: how many participants completed an antigen test within the stated follow-up window, and how do results compare across the relevant randomized pathways? Those outcome counts and comparisons are not reported in the registry record.

3. Trial Design

The registry describes a completed randomized, unmasked, sequential study, with enrollment of 668. Its title and summary identify the aim as optimizing a new adaptive intervention to increase COVID-19 testing among people at high risk in an urban community. The intervention framework adapts the HIV Continuum of Prevention, Care, and Treatment Framework to track testing and follow-up. The study is listed as having no applicable phase.

At the initial stage, participants are randomized to navigation services or brochure only. The arm descriptions then specify that some participants in each initial pathway are randomized to an additional component: brief counseling or critical dialogue. The listed pathways also include navigation followed by navigation and brochure followed by brochure. Thus, the design is sequential: assignment at the initial stage establishes a pathway, and some participants receive a later randomized assignment within that pathway.

All listed interventions are behavioral. Navigation services, critical dialogue, brief counseling, and referral and digital brochure appear among the intervention names. The arm descriptions clarify the navigation and brochure pathways, but the registry record does not explain how referral and digital brochure relates to each listed arm. It also does not report allocation ratios, the exact randomization procedures, eligibility criteria, or the rules determining which participants entered the later randomization.

The primary endpoint is Stage 1 completion of a COVID-19 antigen test within one week of baseline. Although the study is marked completed, completion status is not the same as a posted analysis. The registry record lists no statistical analyses and gives no endpoint counts or comparative estimates. The protocol’s statistical plan, sample-size justification, interim analyses, and analysis populations are not reported in the registry record. Accordingly, the design can be described from the intervention and randomization fields, but the intended inferential procedures cannot be reconstructed from this record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Only the first 6 of 8 groups are shown.

Stage 1: First Intervention

Second Intervention

Analysis population for the primary outcome, as defined in the registry: Population for Stage 1

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: This represents the Stage 2 baseline analysis population.

Only the first 6 of 7 groups are shown.

6. Primary Endpoint

The registry lists the primary outcome as Stage 1: Completion of COVID-19 Test After First Randomization, measured over Stage 1: Within one week of completing baseline..

The primary endpoint is the number of participants who came to the agency and completed a COVID-19 antigen test within one week of completing baseline. It is defined for Stage 1 and expressed as a count of participants. This makes the endpoint a binary outcome at the participant level: each participant either completed the stated testing step during the specified window or did not. The registry presents the measure as a count, not as a percentage or a time-to-event measure.

Using a concrete behavioral endpoint connects the intervention to the study’s stated goal of increasing testing. In general, a measure tied to an observable action can make the outcome definition relatively direct: the relevant event is agency attendance and test completion within the stated period. That definition also limits what the endpoint captures. It does not, by itself, measure later testing, follow-up care, or other health outcomes. The registry identifies follow-up and tracking as part of the broader framework, but the primary endpoint description is specifically about the initial test completion.

The record does not report how many participants completed testing, how many were assessed for the endpoint, or how missing endpoint information was handled. It also does not report estimates comparing the randomized pathways, uncertainty intervals, or significance tests. Therefore, the endpoint’s meaning can be described from its definition, but the amount of testing completion and the precision of any intervention comparison cannot be assessed from the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The methods that can be described are the randomized sequential structure and the binary primary endpoint. The registry identifies the study as randomized, unmasked, and sequential. It lists an initial navigation or brochure pathway and later randomization for some participants to brief counseling or critical dialogue. It defines the primary outcome as the number of participants completing an antigen test at the agency within one week of baseline. The record does not provide the statistical analysis plan or numerical outcome analyses.

What does a randomized sequential design mean?

In general, randomization assigns participants to intervention options by chance. This helps make groups comparable on average with respect to measured and unmeasured characteristics, although the quality of a particular comparison also depends on how randomization was implemented and whether participants were analyzed appropriately. A sequential design uses assignment at an initial decision point and may use further assignment at a later point. Here, the registry describes initial assignment to navigation or brochure and additional randomization for some participants within those pathways. The exact procedures and the rules governing later assignment are not reported in the registry record.

Because assignment can occur at more than one point, an analysis needs to identify which intervention contrast it is estimating. For example, an analysis could focus on the initial pathways or on the later addition of a component within a pathway. These contrasts answer different questions and may involve different eligible participants. The registry record does not report the planned estimands, the exact comparison definitions, or the methods used to account for the sequential assignments. It would therefore be inappropriate to infer a particular analysis from the arm labels alone.

How should a binary endpoint be analyzed?

In general, a binary outcome records whether an event occurred for each participant. Counts of participants with the event can be used to estimate event proportions when the relevant denominators are known. A comparison may be expressed using a difference in proportions, a ratio, or a model-based contrast. Each choice describes the relationship between groups differently, and interpretation depends on the chosen measure, the analysis population, and the model assumptions. The registry reports the endpoint as a participant count but provides neither the event counts nor the denominators needed to interpret a comparison.

Uncertainty is important because an observed group difference is an estimate, not a perfectly precise value. In general, a confidence interval conveys uncertainty around an estimate under the analysis assumptions. A p-value addresses compatibility between the observed data and a specified null model; it is not a measure of effect size or clinical importance. Neither confidence intervals nor p-values for the primary endpoint are reported in the registry record. No effect estimate is reported either, so there is no numerical result to interpret in these terms.

What analysis details remain unknown?

The registry record does not report the statistical model, any covariate adjustment, the handling of repeated or sequential assignments, or the method used to address missing endpoint data. The precise analysis population is also not reported. These details can affect both the estimate and its uncertainty. For instance, an analysis based on participants as randomized can answer a different question from an analysis limited to participants who received or completed an intervention. The record does not indicate which approach was used.

General statistical practice also distinguishes an analysis plan established before outcome review from exploratory analyses conducted after results are examined. The registry does not report the plan or say whether analyses were prespecified. It gives no information about interim analyses, multiplicity adjustments, or sample-size justification. The record’s enrollment figure alone cannot establish what effect the study was designed to detect or whether the completed study had adequate precision.

The sample-size assumptions described in the record concern a planning illustration based on an observed effect, but no corresponding primary effect estimate or planning outputs are reported in the registry record for this record. Such illustrations, when present, should be understood as planning scenarios rather than as observed power. Observed power is not a substitute for interpreting an effect estimate and its uncertainty. Here, neither the effect estimate nor a confidence interval is available, so precision cannot be evaluated.

Overall, the statistical methods explanation must remain bounded by what is registered. The design and endpoint are identifiable; the analysis choices and outcome findings are not. General principles can explain how such a study might be analyzed, but they cannot fill in the unreported model, data handling, comparisons, or results for this trial.

10. Multiplicity, Missing Data and Analysis Populations

The registry record does not report how multiplicity was handled. This matters because the intervention structure includes initial pathways and later randomized components, creating several possible comparisons. If investigators test multiple hypotheses, the chance of at least one apparently unusual result can increase. General methods for addressing multiplicity include defining a primary contrast in advance, adjusting inference across selected comparisons, or treating some analyses as exploratory. The registry record does not say which, if any, approach was planned or used.

The primary endpoint is identified as Stage 1 completion of a COVID-19 test, but the record does not specify a complete hierarchy of outcomes or contrasts. It lists two outcome measures and no analyses. The second outcome’s details are not described in the record details available for this analysis. There are no reported p-values or estimates to assess against any multiplicity procedure.

Missing-data handling is also not reported. The endpoint definition does not explain what happened when a participant’s testing status was unknown, when a participant did not return to the agency, or when other data were unavailable. Those circumstances should not automatically be treated as equivalent. In general, missing-data assumptions and methods can affect estimates, particularly when the reason data are missing is related to intervention assignment or outcome status. No method, sensitivity analysis, or missingness count is reported.

The analysis populations are not reported in the registry record. It is therefore unknown whether analyses were intended to include all randomized participants, only participants with an observed endpoint, or another defined group. The number enrolled does not identify the denominator for the primary endpoint or establish how participants were handled after randomization. Without an analysis population, missing-data procedures, and prespecified comparison plan, the inferential interpretation of any unreported analysis cannot be reconstructed.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry lists serious adverse-event figures for each of the Stage 1 and Stage 2 pathways. For every listed group, the number of serious adverse events is recorded as 0, and deaths are recorded as 0. The listed at-risk counts are 328 for Stage 1: Navigation; 160 for Stage 2: Navigation Followed by Navigation; 36 for Stage 2: Navigation Followed by Brief Counseling; 126 for Stage 2: Navigation Followed by Critical Dialogue; 340 for Stage 1: Brochure; 165 for Stage 2: Brochure Followed by Brochure; 32 for Stage 2: Brochure Followed by Brief Counseling; and 137 for Stage 2: Brochure Followed by Critical Dialogue.

These are registry-reported counts, not comparative estimates. A recorded zero means no serious adverse events were reported for that listed group in this record; it does not demonstrate that the risk was absent. Rare events can be difficult to characterize from a study record, and the registry does not provide event definitions, follow-up duration for safety, or a fuller account of how adverse events were collected. It also does not report a statistical comparison of safety between pathways. The figures should therefore be read as the reported serious-event and death counts, not as evidence that the intervention pathways have identical safety profiles.

12. What the Result Does, and Does Not, Mean

The record supports a description of the study’s purpose, design, intervention pathways, and primary endpoint. It describes a randomized sequential study of behavioral approaches intended to increase COVID-19 testing among people at high risk in an urban community. Its primary endpoint concerns agency attendance and antigen-test completion within one week of baseline. These details clarify the question the study was designed to address.

The record does not support a conclusion about whether testing completion differed among intervention pathways. It reports no primary outcome counts, group-level estimates, confidence intervals, or p-values, and lists no statistical analyses. As a result, neither the size nor the direction of a primary outcome difference can be described. The absence of results in this record should not be interpreted as evidence of no effect, equivalence, or lack of benefit. It is a limit on what can be inferred from the record.

The trial’s enrollment of 668 is not a substitute for outcome information. Enrollment does not show how many participants had an observed endpoint, how many were included in each analysis, or how precisely an effect was estimated. The registry also does not report the statistical plan, missing-data methods, analysis populations, or any multiplicity procedure. These omissions prevent a full appraisal of the intended and completed inference.

Similarly, the listed serious adverse-event counts are descriptive registry entries. Zero reported events in the listed groups does not establish zero risk, and the record does not offer a comparative safety analysis. The findings are therefore limited to the registered design and reported counts. They should not be extended to claims about clinical outcomes, the success of any behavioral component, or the relative merits of intervention sequences.

In general, interpreting an intervention study requires both a clearly defined comparison and an estimate with uncertainty, alongside an understanding of how data were collected and analyzed. The registry record establishes parts of the design and outcome definition but does not provide those inferential results. A careful reading separates what the study set out to measure from what its posted record actually reports.

13. Why This Trial Matters Statistically

This trial is statistically notable for its sequential intervention structure. Rather than evaluating only a single intervention against a single comparator, the registry describes initial assignment to navigation or brochure, followed for some participants by a further randomized behavioral component. Such designs can address questions about intervention sequences and adaptation, but the interpretation depends on carefully defined decision points, eligible groups, and contrasts. The registry record describes the pathways without reporting those analysis details.

The primary endpoint is also concrete: completion of an antigen test at the agency within one week of baseline. That clear event definition can help readers understand what is being counted. It focuses the analysis on a specific behavior within a defined window, rather than directly measuring every aspect of testing, follow-up, or health. Understanding that scope is important when considering what conclusions an endpoint could support.

The record illustrates the distinction between a completed study and a reported statistical result. It lists enrollment and a primary outcome definition, yet it reports no endpoint findings or analyses. For researchers and readers, this underscores why a registered design cannot stand in for a results report. Effect estimates, uncertainty, analysis populations, and data-handling methods are needed to assess the strength and limitations of an empirical conclusion.

Finally, an adaptive or sequential intervention raises questions about multiplicity and interpretation across pathways. Multiple contrasts can be scientifically useful, but they require transparent planning and reporting to distinguish primary from exploratory questions. Because the registry does not report its statistical plan or analyses, the record cannot show how those challenges were handled. Its statistical importance is therefore primarily about design and reporting: it makes the intervention structure visible while leaving the inferential evidence unavailable.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for interpreting this trial from the registry record is the absence of primary outcome results. Although the endpoint is defined, the record does not give completion counts, group denominators, effect estimates, confidence intervals, or significance tests. It lists no statistical analyses. Consequently, the magnitude and precision of any intervention comparison cannot be evaluated.

The sequential design is described in broad terms, but several details needed to understand its comparisons are not reported in the registry record. These include allocation ratios, the procedures for later randomization, the rules determining who entered each later assignment, and the planned contrasts. The relationship between the intervention named referral and digital brochure and the listed arm descriptions is also not explained in the record details.

Important analysis information is missing. The registry record does not report the statistical model, covariate adjustment, analysis populations, missing-data methods, or a multiplicity strategy. The sample-size justification, interim analyses, and prespecified statistical plan are not reported. Without these details, even a result from another source could not be fully interpreted from this registry entry alone.

The primary endpoint covers a specific testing behavior in a specific period, rather than all testing or follow-up outcomes. The record does not report whether other outcome measures were analyzed or how they were defined. The safety figures are also limited: the listed serious adverse-event and death counts are zero, but the record does not provide detailed event definitions, collection procedures, or comparative safety estimates.

These limitations concern the information available in the registry record, not necessarily the full study or any separate report. They mean that conclusions should be confined to the registered design, endpoint definition, and listed safety counts. The record does not allow an assessment of intervention effects or their precision.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Optimization of a New Adaptive Intervention to Increase COVID-19 Testing — NCT04757298.
• Registry record last updated 2024-02-15; status last verified 2024-02.
• Results first posted 2024-02-15.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry identifies NCT04757298 as a completed, randomized, unmasked, sequential study titled “Optimization of a New Adaptive Intervention to Increase COVID-19 Testing.” The study enrolled 668 and concerns COVID-19 testing among people at high risk in an urban community. Its behavioral pathways begin with navigation services or a brochure, with some participants subsequently randomized to brief counseling or critical dialogue.

The primary endpoint is the number of participants completing an antigen test at the agency within one week of baseline. The registry record does not report endpoint counts, comparative estimates, confidence intervals, p-values, or statistical analyses. It also does not report the statistical plan, analysis populations, or missing-data methods. Serious adverse-event and death counts are recorded as 0 in each listed pathway. These registry entries describe the design and reported safety counts but do not establish intervention effects or comparative safety.